Capital investments in production plants represent a significant portion of the cost of new recombinant drugs
Extra column effects must be accounted for to make a valid comparison
Extra column effects must be accounted for to make a valid comparison
Less than 35 percent of all biotech companies have sufficient finances to survive beyond one year.
Over the last three decades, numerous protein expression systems have been developed with various quality requirements on large and small scales. Huge steps have been made in large-scale protein production in mammalian systems while the small-scale mammalian systems are expensive and inflexible. Thus, small-scale production is done in simpler expression systems, sometimes sacrificing the quality of the proteins. However, relief is on the way.
A 20% TSP-producing cultivar can generate up to 265 pounds of crude recombinant protein per acre.
As the fourth largest center for biotechnology and life sciences in the US, New Jersey is home to 15 of the world's 20 largest pharmaceutical companies. More than half of all new medicines approved in the US are developed by New Jersey companies. New Jersey is an ideal location because it offers close proximity to the financial markets in New York and Philadelphia, and a highly skilled workforce, strong funding, government support, and academic expertise.
Web-based asset performance management provides pharmaceutical manufacturing with a number of advantages over traditional asset maintenance and tracking.
The cell density achieved in a CELLine bioreactor is typically 1 to 2 orders of magnitude higher than in a conventional culture vessel
One of the major challenges in fungal biotechnology is preventing proteases of the fungi from degrading recombinant proteins.
...each day a product is delayed is estimated to cost upwards of $1 million to $100 million.
The HSV-1 and HVP-2 titers were determined by the inoculation of test solutions into Vero cell cultures and calculated using the Reed M?ench method.
As biopharma companies rapidly change their focus, they may lack the laboratory space, instrumentation, and the scientific knowledge to support biologics research.
The moral to the story is that the human body is immensely more complex than any computer that we've been able to dream up.
As a company that performs site selection for biopharmaceutical companies worldwide, Fluor Global Location Strategies has witnessed one country truly distinguishing itself from the competition as a worldwide leader in the industry: the United Kingdom. The global competition for biotech investments has been at a fever pitch over the past few years, with varied results.
. . . These new stringent rules will strongly impact the pipeline of scientific talent the NIH has provided the biopharm industry.
Established, fully validated methodology and SOPs are required prior to initiation of any training activities.
Certain areas of the vaccine market appear to be in vogue again, revitalized by blockbusters such as Prevnar, the pneumococcal pneumonia vaccine that reaped $1.5 billion in sales last year, and the human papilloma virus vaccines, which are projected to reach $4 billion per year.
Until now, there was little data on chemical inactivation of CHO cells and other GMM.
Capital investments in production plants represent a significant portion of the cost of new recombinant drugs
"Smart" tags speak only when spoken to. "Brilliant" tags are capable of independent decision-making.
There are challenges aplenty in purification and analysis of PEGylated protein pharmaceuticals. Here are a variety of technical solutions, many concentrating on the chemistry of the linker.
Cancer treatment has grown into a multibillion-dollar business responsible for saving and improving the lives of countless patients each year. One of the approaches generating a flurry of interest is monoclonal antibodies.
Utilizing a measured approach can increase the probability for identifying search criteria that fulfill a company’s strategy.
by Wolfgang Winter, Agilent Technologies GmbH and Ludwig Huber, Agilent Technologies GmbH The rules for electronic records and signatures still remain in effect. The change means that companies must now justify their decisions on whether or not to implement specific electronic controls with documented risk assessments and considerations of the record requirements detailed in the corresponding predicate rule.
One of the critical early tasks of the documentation team is coordinating plans and requirements with the start-up team.